Finance

Lists
Portfolios
Track your investments in one place, get AI insights, and more
Top movers in your lists
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXE
Energy
SIXE
Energy
SIXE
-2.11%
1,205.14
-26.00
-2.11%
1,231.141,233.921,237.061,203.47
SIXV
Health care
SIXV
Health care
SIXV
+1.34%
1,658.73
+21.88
+1.34%
1,636.851,635.521,670.051,635.52
SIXB
Materials
SIXB
Materials
SIXB
+1.20%
1,118.45
+13.30
+1.20%
1,105.151,112.561,125.111,112.56
SIXC
Communications
SIXC
Communications
SIXC
-1.05%
579.08
-6.14
-1.05%
585.22585.22589.50574.23
SIXU
Utilities
SIXU
Utilities
SIXU
-1.01%
883.81
-8.98
-1.01%
892.79892.85892.86876.43
US market summary
The Dow Jones Industrial Average achieved its third consecutive record high and fifth positive session in a row, supported by strong corporate earnings reports. In contrast, the S&P 500 and the Nasdaq Composite retreated from recent highs due to a broad cooling in mega-cap technology and semiconductor shares.
Dive deeper with AI
Massive artificial intelligence spending triggers sharp drop in SpaceX stock
SpaceX shares fell over 13% following its first quarterly earnings release since going public in June. Although the reusable rocket manufacturer managed to beat top-line revenue estimates, investors grew anxious over its heavy capital expenditures to support internal data centers and computing infrastructure.
Dive deeper with AI
Nvidia secures exclusivity with SpaceX as other tech giants face leadership shakeups
Nvidia shares jumped more than 3% following an announcement that its processors would be exclusively used for SpaceX's artificial intelligence infrastructure. Conversely, other market leaders struggled, with Google's parent Alphabet losing ground after announcing a restructuring of its AI divisions and the departure of its chief scientist.
Dive deeper with AI
Eli Lilly shares jump on resilient global demand for core treatments
Shares of Eli Lilly surged approximately 5% on the back of second-quarter earnings that surpassed consensus expectations. Financial results were heavily bolstered by strong international performance in the company's flagship treatments for obesity and diabetes.
Dive deeper with AI
Latest updates
Live
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
Google apps